---
layout: default
title: Alpha -Tocopherol Ascorbic Acid Aspirin Salix Alba
parent: 僅模型預測 (L5)
nav_order: 236
evidence_level: L5
indication_count: 0
---

# Alpha -Tocopherol Ascorbic Acid Aspirin Salix Alba
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Alpha-Tocopherol / Ascorbic Acid / Aspirin / Salix Alba Bark / Vitamin A: No TxGNN Repurposing Prediction Available

## One-Sentence Summary

This is a five-component combination product containing Vitamin E (alpha-tocopherol), Vitamin C (ascorbic acid), Aspirin, White Willow Bark (*Salix alba* bark), and Vitamin A — an antioxidant and anti-inflammatory blend with no approved indication on record in the queried regulatory database.
The TxGNN model did not generate any repurposing predictions for this combination, as the product lacks a DrugBank ID required for knowledge-graph mapping.
Without a model prediction or supporting evidence, this candidate cannot proceed to formal evaluation at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available (no regulatory record found) |
| Predicted New Indication | None generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction only; no supporting studies |
| Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The TxGNN model requires a valid DrugBank ID to anchor a drug to the biomedical knowledge graph. This submission is a **multi-ingredient combination** with no unified DrugBank entry, so the model pipeline could not produce a prediction.

Each individual ingredient does have an established mechanistic profile:

| Ingredient | Known Role | Individual DrugBank ID |
|---|---|---|
| Aspirin (Acetylsalicylic acid) | COX-1/COX-2 inhibitor — anti-inflammatory, analgesic, antiplatelet | DB00945 |
| Alpha-Tocopherol (Vitamin E) | Fat-soluble antioxidant; protects cell membranes from lipid peroxidation | DB00163 |
| Ascorbic Acid (Vitamin C) | Water-soluble antioxidant; supports collagen synthesis and immune defence | DB00126 |
| Salix Alba Bark (White Willow) | Salicin-containing botanical; metabolised to salicylate — anti-inflammatory | DB13156 |
| Vitamin A (Retinol) | Regulates cell differentiation, vision, and innate immune function | DB00162 |

Together, the combination presents a dual-pathway profile — **antioxidant (Vitamins A, C, E) + salicylate-based anti-inflammatory (Aspirin + Salix alba)** — but without a unified identifier and without a documented original indication, the TxGNN pipeline has no entry point to generate predictions.

A potential concern specific to this combination: **Aspirin and Salix alba bark are both salicylate sources**, raising the question of whether the formulation inadvertently duplicates pharmacological activity and increases salicylate exposure.

---

## Safety Considerations

No structured safety data (warnings or contraindications) was retrieved for this combination as a unified product. The following notes are derived from the known profiles of the individual components:

- **Dual salicylate burden**: The co-presence of Aspirin and Salix alba bark means two independent salicylate sources. This may increase the risk of salicylate toxicity, gastrointestinal irritation, and bleeding — particularly relevant in elderly patients or those already on anticoagulant therapy.
- **Potential drug interactions**: Aspirin interacts with warfarin, other NSAIDs, SSRIs, and methotrexate. A combined product amplifies these risks without being formally tracked under a single drug entry.
- **Fat-soluble vitamin accumulation**: Alpha-tocopherol and Vitamin A are both fat-soluble; chronic high-dose use carries a risk of hypervitaminosis A (teratogenicity, hepatotoxicity) and, at very high Vitamin E doses, paradoxical pro-oxidant or anticoagulant effects.

Please refer to the package inserts of each individual ingredient for full safety information until a unified monograph is available.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This combination product cannot be evaluated by the TxGNN pipeline in its current form — it lacks a DrugBank ID, approved indication, and model predictions. The regulatory record is empty and safety data is unavailable. Proceeding without these inputs would produce an assessment without evidentiary foundation.

**To proceed, the following is needed:**

- **Decompose and re-run individually**: Submit each of the five ingredients separately through the TxGNN pipeline using their individual DrugBank IDs (DB00945, DB00163, DB00126, DB13156, DB00162), then aggregate and compare predicted indications for mechanistic overlap.
- **Clarify product intent**: Determine the intended therapeutic or preventive use of this specific combination — i.e., why these five ingredients are co-formulated. This drives the "original indication" anchor for repurposing analysis.
- **Obtain safety documentation**: Download and parse the package insert (if any exists) or equivalent product monograph to populate warnings and contraindications.
- **Verify salicylate dosing**: Quantify the total salicylate contribution from both Aspirin and Salix alba bark to assess duplication risk before any clinical evaluation.
- **Resolve regulatory status**: Confirm whether this combination holds an authorisation in any jurisdiction (EU, US, Japan, etc.) — the Taiwan query returned zero results but a DrugBank query returned one result, suggesting partial data may exist.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

